Key facts
- Notable investors include Creative Destruction Lab, University of Toronto, Blue Owl Capital, Foresite Capital, Logos Capital — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for SeraGene Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for SeraGene Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SeraGene Therapeutics
Developer of ribonucleic acid-based therapeutics designed to provide long-lasting control over coagulation disorders. The company offers liver-targeted RNA agents, nanomedicine delivery systems, and a diversified preclinical pipeline, enabling healthcare providers to manage bleeding and thrombotic conditions with reduced treatment burden and improved safety for underserved patient populations.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2022
- Employees
- 7
- Website
- seragenetx.com/
- Ownership
- Privately Held (backing)
SeraGene Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SeraGene Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SeraGene Therapeutics in its N-PORT filings yet. We sweep new filings monthly.